Mechanisms of protein-folding diseases at a glance

DMM Disease Models and Mechanisms

Volumn 7, Issue 1, 2014, Pages 9-14

  Valastyan, Julie S ^a,b   Lindquist, Susan ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Disease; Misfolding; Protein; Yeast

Indexed keywords

AMYLOID; CHAPERONE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MUTANT PROTEIN; PREALBUMIN; PROTEIN P53;

ALZHEIMER DISEASE; ARTICLE; CONFORMATIONAL TRANSITION; EPIDERMOLYSIS BULLOSA SIMPLEX; GAUCHER DISEASE; HUMAN; INTERMEDIATE FILAMENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN MISFOLDING;

DISEASE; MISFOLDING; PROTEIN; YEAST;

AMYLOID; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; GAUCHER DISEASE; GENES, DOMINANT; HUMANS; MOLECULAR CHAPERONES; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 84892408458     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.013474     Document Type: Article

References (72)

1. Aidoo, M., Terlouw, D. J., Kolczak, M. S., McElroy, P. D., ter Kuile, F. O., Kariuki, S., Nahlen, B. L., Lal, A. A. and Udhayakumar, V. (2002). Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 359, 1311-1312.
2. Bijlmakers, M. J. and Marsh, M. (2000). Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol. Biol. Cell 11, 1585-1595.
3. Brodbeck, J., McGuire, J., Liu, Z. P., Meyer-Franke, A., Balestra, M. E., Jeong, D. E., Pleiss, M., McComas, C., Hess, F., Witter, D. et al. (2011). Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217-17226.
4. Caughey, B. and Lansbury, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298.
5. Chamcheu, J. C., Siddiqui, I. A., Syed, D. N., Adhami, V. M., Liovic, M. and Mukhtar, H. (2011a). Keratin gene mutations in disorders of human skin and its appendages. Arch. Biochem. Biophys. 508, 123-137.
6. Chamcheu, J. C., Navsaria, H., Pihl-Lundin, I., Liovic, M., Vahlquist, A. and Törmä, H. (2011b). Chemical chaperones protect epidermolysis bullosa simplex keratinocytes from heat stress-induced keratin aggregation: involvement of heat shock proteins and MAP kinases. J. Invest. Dermatol. 131, 1684-1691.
7. Chamcheu, J. C., Wood, G. S., Siddiqui, I. A., Syed, D. N., Adhami, V. M., Teng, J. M. and Mukhtar, H. (2012). Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Exp. Dermatol. 21, 481-489.
8. Chen, H. K., Ji, Z. S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y. D. and Mahley, R. W. (2011). Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J. Biol. Chem. 286, 5215-5221.
9. Chiti, F. and Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366.
10. Cox, T. M. and Cachón-González, M. B. (2012). The cellular pathology of lysosomal diseases. J. Pathol. 226, 241-254.
11. Dill, K. A. and MacCallum, J. L. (2012). The protein-folding problem, 50 years on. Science 338, 1042-1046.
12. Dong, L. M. and Weisgraber, K. H. (1996). Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271, 19053-19057.
13. Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H. and Agard, D. A. (1994). Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269, 22358-22365.
14. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A. and Wanker, E. E. (2008). EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566.
15. Ellis, R. J. and Minton, A. P. (2006). Protein aggregation in crowded environments. Biol. Chem. 387, 485-497.
16. Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., Myers, R. H., Pericak-Vance, M. A., Risch, N., van Duijn, C. M.; APOE and Alzheimer Disease Meta Analysis Consortium (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278, 1349-1356.
17. Freed-Pastor, W. A. and Prives, C. (2012). Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286.
18. Friedman, P. N., Chen, X., Bargonetti, J. and Prives, C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90, 3319-3323.
19. Futerman, A. H. and van Meer, G. (2004). The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 554-565.
20. Gavrin, L. K., Denny, R. A. and Saiah, E. (2012). Small molecules that target protein misfolding. J. Med. Chem. 55, 10823-10843.
21. Gibson, J. S. and Ellory, J. C. (2002). Membrane transport in sickle cell disease. Blood Cells Mol. Dis. 28, 303-314.
22. Glabe, C. G. (2004). Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 29, 542-547.
23. Grabowski, G. A. (2008). Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263-1271.
24. Hartl, F. U., Bracher, A. and Hayer-Hartl, M. (2011). Molecular chaperones in protein folding and proteostasis. Nature 475, 324-332.
25. Hidvegi, T., Schmidt, B. Z., Hale, P. and Perlmutter, D. H. (2005). Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and - 12, NFkappaB, and BAP31 but not the unfolded protein response. J. Biol. Chem. 280, 39002-39015.
26. Hidvegi, T., Ewing, M., Hale, P., Dippold, C., Beckett, C., Kemp, C., Maurice, N., Mukherjee, A., Goldbach, C., Watkins, S. et al. (2010). An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329, 229-232.
27. Hunt, J. A. and Ingram, V. M. (1959). A terminal peptide sequence of human haemoglobin? Nature 184 Suppl. 9, 640-641.
28. Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q. and Lee, V. M. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024-1037.
29. Ingram, V. M. (1957). Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature 180, 326-328.
30. Jarosz, D. F., Taipale, M. and Lindquist, S. (2010). Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. Annu. Rev. Genet. 44, 189-216.
31. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. and Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
32. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
33. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. and Lansbury, P. T., Jr (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
34. Lindquist, S. L. and Kelly, J. W. (2011). Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb. Perspect. Biol. 3, a004507.
35. Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J. and Fersht, A. R. (2013). Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41, 6034-6044.
36. Lomas, D. A., Evans, D. L., Finch, J. T. and Carrell, R. W. (1992). The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357, 605-607.
37. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J. Q. and Lee, V. M. (2012). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953.
38. Ma, J. Y., Yee, A., Brewer, H. B., Jr, Das, S. and Potter, H. (1994). Amyloidassociated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92-94.
39. Maestri, N. E., Brusilow, S. W., Clissold, D. B. and Bassett, S. S. (1996). Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335, 855-860.
40. Mallya, M., Phillips, R. L., Saldanha, S. A., Gooptu, B., Brown, S. C., Termine, D. J., Shirvani, A. M., Wu, Y., Sifers, R. N., Abagyan, R. et al. (2007). Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J. Med. Chem. 50, 5357-5363.
41. Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M. and Cyr, D. M. (2001). The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3, 100-105.
42. Milner, J. and Medcalf, E. A. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774.
43. Milner, J., Medcalf, E. A. and Cook, A. C. (1991). Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11, 12-19.
44. Mohanka, M., Khemasuwan, D. and Stoller, J. K. (2012). A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin. Biol. Ther. 12, 685-700.
45. Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J. and Hallbeck, M. (2012). Spreading of neurodegenerative pathology via neuron-toneuron transmission of beta-amyloid. J. Neurosci. 32, 8767-8777.
46. Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W. and Pitas, R. E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850-852.
47. Nedelsky, N. B., Todd, P. K. and Taylor, J. P. (2008). Autophagy and the ubiquitinproteasome system: collaborators in neuroprotection. Biochim. Biophys. Acta 1782, 691-699.
48. Perchiacca, J. M., Ladiwala, A. R., Bhattacharya, M. and Tessier, P. M. (2012). Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Proc. Natl. Acad. Sci. USA 109, 84-89.
49. Qu, B. H., Strickland, E. H. and Thomas, P. J. (1997). Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J. Biol. Chem. 272, 15739-15744.
50. Razavi, H., Palaninathan, S. K., Powers, E. T., Wiseman, R. L., Purkey, H. E., Mohamedmohaideen, N. N., Deechongkit, S., Chiang, K. P., Dendle, M. T., Sacchettini, J. C. et al. (2003). Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. Int. Ed. Engl. 42, 2758-2761.
51. Ron, I. and Horowitz, M. (2005). ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387-2398.
52. Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O. and Klionsky, D. J. (2007). Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 6, 304-312.
53. Russell, D., Andrews, P. D., James, J. and Lane, E. B. (2004). Mechanical stress induces profound remodelling of keratin filaments and cell junctions in epidermolysis bullosa simplex keratinocytes. J. Cell Sci. 117, 5233-5243.
54. Sawkar, A. R., Cheng, W. C., Beutler, E., Wong, C. H., Balch, W. E. and Kelly, J. W. (2002). Chemical chaperones increase the cellular activity of N370S betaglucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA 99, 15428-15433.
55. Sawkar, A. R., Adamski-Werner, S. L., Cheng, W. C., Wong, C. H., Beutler, E., Zimmer, K. P. and Kelly, J. W. (2005). Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 12, 1235-1244.
56. Sawkar, A. R., D'Haeze, W. and Kelly, J. W. (2006). Therapeutic strategies to ameliorate lysosomal storage disorders-a focus on Gaucher disease. Cell. Mol. Life Sci. 63, 1179-1192.
57. Sekijima, Y., Dendle, M. A. and Kelly, J. W. (2006). Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13, 236-249.
58. Skinner, R., Chang, W. S., Jin, L., Pei, X., Huntington, J. A., Abrahams, J. P., Carrell, R. W. and Lomas, D. A. (1998). Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. J. Mol. Biol. 283, 9-14.
59. Smith, M. H., Ploegh, H. L. and Weissman, J. S. (2011). Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 334, 1086-1090.
60. Surguchev, A. and Surguchov, A. (2010). Conformational diseases: looking into the eyes. Brain Res. Bull. 81, 12-24.
61. Taipale, M., Krykbaeva, I., Whitesell, L., Santagata, S., Zhang, J., Liu, Q., Gray, N. S. and Lindquist, S. (2013). Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630-637.
62. Trepel, J., Mollapour, M., Giaccone, G. and Neckers, L. (2010). Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537-549.
63. Treusch, S., Cyr, D. M. and Lindquist, S. (2009). Amyloid deposits: protection against toxic protein species? Cell Cycle 8, 1668-1674.
64. Varshavsky, A. (2012). The ubiquitin system, an immense realm. Annu. Rev. Biochem. 81, 167-176.
65. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C. et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
66. Wang, X. D., Venable, J., LaPointe, P., Hutt, D. M., Koulov, A. V., Coppinger, J., Gurkan, C., Kellner, W., Matteson, J., Plutner, H. et al. (2006). Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127, 803-815.
67. Werner, N. S., Windoffer, R., Strnad, P., Grund, C., Leube, R. E. and Magin, T. M. (2004). Epidermolysis bullosa simplex-type mutations alter the dynamics of the keratin cytoskeleton and reveal a contribution of actin to the transport of keratin subunits. Mol. Biol. Cell 15, 990-1002.
68. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. and Neckers, L. M. (1994). Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91, 8324-8328.
69. Whitesell, L., Santagata, S. and Lin, N. U. (2012). Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr. Mol. Med. 12, 1108-1124.
70. Wolfe, K. J. and Cyr, D. M. (2011). Amyloid in neurodegenerative diseases: friend or foe? Semin. Cell Dev. Biol. 22, 476-481.
71. Xu, Y. and Lindquist, S. (1993). Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Natl. Acad. Sci. USA 90, 7074-7078.
72. Xu, Y., Singer, M. A. and Lindquist, S. (1999). Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl. Acad. Sci. USA 96, 109-114.